For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 85 | |||
| General and administrative | 6,875 | |||
| Total costs and expenses | 6,960 | |||
| Loss from operations | -6,960 | |||
| Change in fair value of warrant liability | 3,161 | |||
| Gain on sale of assets | 37 | |||
| Other (expenses)/income, net | -261 | |||
| Loss before tax | -10,345 | |||
| Net loss | -10,345 | |||
| Deemed dividend relating to warrant exchange | -618 | |||
| Net loss attributable to common shareholders | -10,963 | |||
| Basic EPS | -2 | |||
| Diluted EPS | -2 | |||
| Basic Average Shares | 5,474,129 | |||
| Diluted Average Shares | 5,474,129 | |||
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)